Skip to NavigationSkip to content

News

0
FDA rejects Mallinckrodt's abuse-deterrent version of opioid painkiller Roxicodone
Mallinckrodt has hit a snag in its quest to bring an abuse-deterrent version of Roxicodone (oxycodone hydrochloride) to market in the US, as it...
0
Scottish Medicines Consortium approves Verkazia for severe eye condition in children and adolescents
The Scottish Medicines Consortium has awarded approval to Santen's eye drops emulsion Verkazia for the treatment of severe vernal...
0
Amgen donate $2m towards increasing diversity in clinical trials
American multinational Amgen has teamed up with the Lazarex Cancer Foundation in support of an initiative aimed at increasing access to clinical...
0
Atopic dermatitis market set to almost triple in value over next 10 years
The atopic dermatitis (eczema) market is expected to reach $18.3 billion by 2027, according to analytics firm GlobalData.
>> More News Stories

Features

Psychedelic therapy: A new approach to mental health

In November 2018, a Phase 2 clinical trial foundthat 76% of patients who underwent MDMA-assisted psychotherapy no longer had PTSD, twelve months...

>> More Features
>> More News Stories